Cytogenetic response to prior treatment with interferon-α is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia

Leukemia

Volumn 20, Issue 3, 2006, Pages 477-484

  Maywald, O ^a   Pfirrmann, M ^b,c   Berger, U ^a   Breitscheidel, L ^b   Gratwohl, A ^d   Kolb, H J ^e   Beelen, D W ^f   Tobler, A ^g   Metzgeroth, G ^a   Gnad, S U ^a   Hochhaus, A ^a   Hasford, J ^b   Hehlmann, R ^a   Reiter, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Gesellschaft für Informationsverarbeitung und Statistik in der Medizin e V   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

Allogeneic stem cell transplantation; Chronic myeloid leukemia; Cytogenetic response; Interferon alpha

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CORRELATION ANALYSIS; FEMALE; GERMANY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECURRENCE RISK; SCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; WHOLE BODY RADIATION;

EID: 33644507112     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404100     Document Type: Article

References (22)

1. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
2. Paschka P, Muller MC, Merx K, Kreil S, Schoch C, Lahaye T et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 2003; 17: 1687-1694.
3. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092.
4. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood 1999; 94: 1517-1536.
5. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: A study of complete cytogenetic responders. Blood 2001; 98: 3074-3081.
6. Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 2003; 17: 1529-1537.
7. McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000; 95: 2219-2225.
8. Venditti A, Maurillo L, Buccisano F, Del Poeta G, Mazzone C, Tamburini A et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 2003; 17: 2178-2182.
9. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064-4077.
10. Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 3668-3677.
11. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850-858.
12. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
13. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 1988; 16: 1141-1154.
14. Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981-2990.
15. Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92: 394-401.
16. Beelen DW, Elmaagacli AH, Schaefer UW. The adverse influence of pretransplant interferon-alpha (IFN-alpha) on transplant outcome after marrow transplantation for chronic phrase chronic myelogenous leukemia increases with the duration of IFN-alpha exposure. Blood 1999; 93: 1779-1780.
17. Giralt S, Szydlo R, Goldman JM, Veum-Stone J, Biggs JC, Herzig RH et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: An analysis from the international bone marrow transplant registry. Blood 2000; 95: 410-415.
18. Lee SJ, Klein JP, Anasetti C, Antin JH, Loberiza FR, Bolwell BJ et al. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 2001; 98: 3205-3211.
19. Pigneux A, Tanguy ML, Michallet M, Jouet JP, Kuentz M, Vernant JP et al. Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Br J Haematol 2002; 116: 193-201.
20. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993; 82: 2235-2238.
21. Gratwohl A. Does early stem-cell transplantation have a role in chronic myeloid leukaemia? For the proposal. Lancet Oncol 2005; 6: 721-722.
22. Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A, Gutierrez-Aguirre CH, Vela-Ojeda J, Garcia-Ruiz-Esparza MA et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043-1047.